Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: A pilot trial

Keyphrases

• Radiation Therapy 100%
• Neoadjuvant Chemotherapy 100%
• Locally Advanced Rectal Cancer 100%
• Transanal Total Mesorectal Excision (taTME) 100%
• R0 Resection 60%
• FOLFIRINOX 60%
• Rectal Cancer 60%
• Chemotherapy 40%
• Bevacizumab 40%
• Concurrent Chemoradiotherapy 40%
• Preoperative Chemotherapy 40%
• Local Recurrence Rate 40%
• Preoperative Radiation 40%
• Patient Selection 20%
• Cardiovascular Toxicity 20%
• Tumor Regression 20%
• Phase II Trial 20%
• Randomized Phase III Trial 20%
• Disease-free Survival 20%
• Cooperative Group 20%
• Single Center 20%
• Consistent Use 20%
• Chemotherapy Alone 20%
• Progressive Disease 20%
• Group Network 20%
• Pathological Complete Response 20%
• Oxaliplatin 20%
• Chemoradiotherapy 20%
• Complete Response Rate 20%
• R0 Resection Rate 20%
• Low Anterior Resection 20%
• Neoadjuvant Chemoradiotherapy (nCRT) 20%
• Preoperative Assessment 20%
• 5-fluorouracil/leucovorin 20%
• Postoperative Radiation 20%

Medicine and Dentistry

• Rectum Cancer 100%
• Neoadjuvant Chemotherapy 100%
• Total Mesorectal Excision 100%
• Radiation Therapy 100%
• Chemoradiotherapy 80%
• Clinical Stage 60%
• Chemotherapy 60%
• FOLFOX 60%
• Bevacizumab 40%
• Recurrence Risk 40%
• Preoperative Radiotherapy 40%
• Preoperative Chemotherapy 40%
• Clinician 20%
• Cardiovascular Toxicity 20%
• Tumor Regression 20%
• Disease Free Survival 20%
• Fluorouracil 20%
• Phase II Trials 20%
• Study Participant 20%
• Preoperative Evaluation 20%
• Progressive Disease 20%
• Oxaliplatin 20%
• Folinic Acid 20%
• Lower Anterior Resection 20%
• Phase III Trials 20%